WaveMan
WaveMan · Company
AVTX · Avalo Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AVTX Avalo Therapeutics (AVTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001534120
Quote by TradingView
Form 144 · 6
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
103
13F, latest reported quarter
Conversions, 180 days
22
Codes C/M, not in net · $3.8M priced

What the filings say about AVTX

Insiders, 180 days
-$7.5M net sold
5 sellers · 9% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.2M
6 notices

Avalo Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Avalo Therapeutics, Inc. insiders sold a net $7.5M of stock across 113 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Sullivan Christopher Ryan
Chief Financial Officer
SELL
2026-09-18 SECtraded 2026-09-16
12,394
$202.4K
-58.1%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (2 buys, 16 sales), the last on Sep 10, 2026.
  • -79.8% median (-79.8% mean) 90-day return after 2 previous buys.
  • The trade is 31.1% of the 39,900 shares held after it.
  • 1 other insider sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Sullivan Christopher Ryan sold about $202.4K of AVTX under a 10b5-1 plan on Sep 16, 2026; 1 other insider sold within 30 days and 103 funds added in the latest 13F quarter.
Sullivan Christopher Ryan
Chief Financial Officer
SELL
2026-09-11 SECtraded 2026-09-10
10,185
$179.5K
-58.2%
Context
  • 17 earlier Form 4 trades (code P or S) here by this insider (2 buys, 15 sales), the last on Aug 18, 2026.
  • -79.8% median (-79.8% mean) 90-day return after 2 previous buys.
  • The trade is 25.5% of the 39,900 shares held after it.
  • 2 other insiders sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Sullivan Christopher Ryan sold about $179.5K of AVTX under a 10b5-1 plan on Sep 10, 2026; 2 other insiders sold within 30 days and 103 funds added in the latest 13F quarter.
Doyle Mittie
Chief Medical Officer
SELL
2026-09-01 SECtraded 2026-08-28
679
$13.6K
-65.0%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Aug 17, 2026.
  • The trade is 1.3% of the 51,776 shares held after it.
  • 2 other insiders sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Doyle Mittie sold about $13.6K of AVTX under a 10b5-1 plan on Aug 28, 2026; 2 other insiders sold within 30 days and 103 funds added in the latest 13F quarter.
Sullivan Christopher Ryan
Chief Financial Officer
SELL
2026-08-19 SECtraded 2026-08-18
31,031
$622.3K
-65.8%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (2 buys, 14 sales), the last on Aug 17, 2026.
  • -79.8% median (-79.8% mean) 90-day return after 2 previous buys.
  • The trade is 77.8% of the 39,900 shares held after it.
  • 2 other insiders sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Sullivan Christopher Ryan sold about $622.3K of AVTX on Aug 18, 2026; 2 other insiders sold within 30 days and 103 funds added in the latest 13F quarter.
Sullivan Christopher Ryan
Chief Financial Officer
SELL
2026-08-19 SECtraded 2026-08-17
37,945
$753.3K
-65.8%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (2 buys, 12 sales), the last on May 7, 2026.
  • -79.8% median (-79.8% mean) 90-day return after 2 previous buys.
  • The trade is 86.9% of the 43,649 shares held after it.
  • 2 other insiders sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Sullivan Christopher Ryan sold about $753.3K of AVTX on Aug 17, 2026; 2 other insiders sold within 30 days and 103 funds added in the latest 13F quarter.
113 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 108 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$7.5M over 180 days
-$1.9M over 90 days
below 82% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
103 funds bought in last quarter
more than 70% of Pharma & Biotech
Revenue
-86.6% year over year
below 88% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
28.4% of the float short (float per yahoo 2026-10-26) · 8.8 days to cover · settled 2026-09-30
more than 95% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AVTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-57.1%12M
-57%-23%+11%+45%2025-102025-122026-022026-042026-062026-082026-10 2026-05-06 · Doyle Mittie sold $952.8K2026-08-17 · Sullivan Christopher Ryan sold $753.3K2026-05-06 · VARKI PAUL sold $706.8K2026-08-18 · Sullivan Christopher Ryan sold $622.3K2026-05-06 · Doyle Mittie sold $496.5K2026-05-06 · VARKI PAUL sold $484.6K2026-05-07 · Sullivan Christopher Ryan sold $448.8K2026-05-06 · Doyle Mittie sold $426.1K2026-03-16 · Doyle Mittie sold $411.7K2026-05-06 · Sullivan Christopher Ryan sold $256.6K2026-05-06 · Sullivan Christopher Ryan sold $238.1K2026-05-06 · Doyle Mittie sold $230.1K2026-05-06 · VARKI PAUL sold $210.0K2026-09-16 · Sullivan Christopher Ryan sold $202.4K2026-05-06 · Sullivan Christopher Ryan sold $200.9K2026-05-06 · Sullivan Christopher Ryan sold $197.0K2026-09-10 · Sullivan Christopher Ryan sold $179.5K2026-04-01 · Sullivan Christopher Ryan sold $125.9K2025-11-14 · Goldman Jonathan sold $117.7K2026-04-30 · Sullivan Christopher Ryan sold $111.9K2026-04-29 · Sullivan Christopher Ryan sold $110.7K2026-04-02 · Sullivan Christopher Ryan sold $105.5K2026-05-06 · VARKI PAUL sold $102.8K2026-05-06 · Doyle Mittie sold $98.2K2026-06-30 · Doyle Mittie sold $93.1K2026-08-17 · Sullivan Christopher Ryan sold $74.8K2026-05-06 · Chan Mitchell sold $72.5K2026-04-06 · Doyle Mittie sold $71.5K2026-05-15 · Doyle Mittie sold $56.3K2026-05-06 · Sullivan Christopher Ryan sold $56.1K2026-08-11 · Riley Jennifer sold $52.0K2025-11-14 · Goldman Jonathan sold $45.3K2026-04-02 · Sullivan Christopher Ryan sold $31.3K2026-05-05 · Doyle Mittie sold $26.9K2026-06-23 · Doyle Mittie sold $26.1K2026-07-27 · Doyle Mittie sold $20.0K2026-08-17 · Doyle Mittie sold $20.0K2026-08-10 · Doyle Mittie sold $13.6K2026-08-28 · Doyle Mittie sold $13.6K2026-04-01 · Doyle Mittie sold $10.9K2026-05-28 · Doyle Mittie sold $10.9K2026-05-06 · VARKI PAUL sold $9.5K2026-08-18 · CHRISTOPHER RYAN SULLIVAN filed to sell $622.2K2026-08-17 · CHRISTOPHER RYAN SULLIVAN filed to sell $74.8K2026-08-17 · CHRISTOPHER RYAN SULLIVAN filed to sell $1.4M2026-08-17 · MITTIE DOYLE filed to sell $98.7K2026-08-11 · JENNIFER RILEY filed to sell $52.0K2026-08-10 · MITTIE DOYLE filed to sell $12.4K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AVTX: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
5,100,216 sh
$94.3M
BlackRock, Inc.
4,365,553 sh
$80.7M
Nantahala Capital Management, LLC
3,724,500 sh
$68.8M
Deep Track Capital, LP
3,610,000 sh
$66.7M
Caligan Partners LP
3,163,866 sh
$58.5M

Congress trades in AVTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AVTX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
CHRISTOPHER RYAN SULLIVAN
Filed 2026-08-18
$622.2K
CHRISTOPHER RYAN SULLIVAN
Filed 2026-08-17
$74.8K
CHRISTOPHER RYAN SULLIVAN
Filed 2026-08-17
$1.4M
MITTIE DOYLE
Filed 2026-08-17
$98.7K
JENNIFER RILEY
Filed 2026-08-11
$52.0K

AVTX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$384.3K position · as of 2026-07-31
0.8%
Fidelity Advisor Biotechnology Fund
$11.7M position · as of 2026-07-31
0.5%
Small Cap Core Portfolio
$3.5M position · as of 2026-06-30
0.4%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$37.5M position · as of 2026-06-30
0.3%
T. Rowe Price Health Care ETF
$79.2K position · as of 2026-06-30
0.3%
PROFUND VP BIOTECHNOLOGY
$166.3K position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
2
Phase 2
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $7.5M sold by insiders over 180 days, 103 funds added last quarter, $2.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

AVTX financials

Revenue growth
-86.6%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$68.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.03x
long-term 2019-09-30 (82 months older than the period end) plus current 2019-09-30 (82 months older than the period end); equity 2026-06-30
Cash flow to debt
-4.46x
TTM operating cash flow over long-term 2019-09-30 (82 months older than the period end) plus current 2019-09-30 (82 months older than the period end)
Return on equity
-36.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-32.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-31.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$293.0M
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term 2019-09-30 (82 months older than the period end) plus current 2019-09-30 (82 months older than the period end), minus cash 2026-06-30
FCF yield
-18.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$59.0K$441.0K$1.9M$18.1M
Operating income-$72.9M-$68.5M-$27.4M-$37.4M
Net income-$78.3M-$35.1M-$31.5M-$41.7M
EPS (diluted)-5.84-20.91-113.58-1,063.00
Operating cash flow-$51.5M-$49.1M-$30.7M-$26.8M
Cash$15.9M$134.5M$7.4M$13.2M
SEC XBRL, fiscal years, as known on 2026-10-27

AVTX Stock Sonar score 6/7 axes

Find similar shapesCompare

AVTX ranks highest on institutional and government (70th percentile) and profitability (63rd), and lowest on risk and compliance (5th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
63
Inputs
  • Return on equity-36.3% · 63 pct, sector of 545
  • Return on assets-32.5% · 58 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-31.1% · 67 pct, sector of 576
Financial health
49
Inputs
  • Debt to equity0.03x · 66 pct, sector of 352
  • Cash flow to debt-4.46x · 32 pct, sector of 371
Growth
12
Inputs
  • Revenue growth, YoY-86.6% · 12 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
8
Inputs
  • Net Form 4 buying (codes P and S), 180d-$7.1M · 17 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
70
Inputs
  • Funds adding, latest quarter103 · 70 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
5
Inputs
  • Short interest, % of float+28.4% · 5 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+47.0% · 5 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AVTX filings, in plain words

Are Avalo Therapeutics insiders buying or selling AVTX?

In the 180 days to 2026-10-27, Avalo Therapeutics insiders were net sellers, a net $7.5M across purchases and sales reported on Form 4, by 5 sellers.

Are there planned insider sales of AVTX?

Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $2.2M of stock; the latest, by CHRISTOPHER RYAN SULLIVAN, was filed 2026-08-18.

Read the full summary

In the 180 days to 2026-10-27, Avalo Therapeutics insiders were net sellers of AVTX, a net $7.5M across purchases and sales reported on Form 4 by 5 sellers. 9% of the 33 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $2.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies